Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 17881889)

1.

Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines.

Schwartz EJ, Bodine EN, Blower S.

Hum Vaccin. 2007 Nov-Dec;3(6):231-8.

2.

Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.

Dhankani V, Kutz JN, Schiffer JT.

PLoS Comput Biol. 2014 Nov 6;10(11):e1003922. doi: 10.1371/journal.pcbi.1003922. eCollection 2014 Nov.

3.

Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding.

Schiffer JT, Mayer BT, Fong Y, Swan DA, Wald A.

J R Soc Interface. 2014 Mar 26;11(95):20140160. doi: 10.1098/rsif.2014.0160. Print 2014 Jun 6.

4.

Status of prophylactic and therapeutic genital herpes vaccines.

Awasthi S, Friedman HM.

Curr Opin Virol. 2014 Jun;6:6-12. doi: 10.1016/j.coviro.2014.02.006. Epub 2014 Mar 12. Review.

PMID:
24631871
5.

HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.

Zhu XP, Muhammad ZS, Wang JG, Lin W, Guo SK, Zhang W.

Viruses. 2014 Jan 24;6(2):371-90. doi: 10.3390/v6020371. Review.

6.

Current thinking on genital herpes.

Hofstetter AM, Rosenthal SL, Stanberry LR.

Curr Opin Infect Dis. 2014 Feb;27(1):75-83. doi: 10.1097/QCO.0000000000000029. Review.

PMID:
24335720
7.

Current status and prospects for development of an HSV vaccine.

Johnston C, Koelle DM, Wald A.

Vaccine. 2014 Mar 20;32(14):1553-60. doi: 10.1016/j.vaccine.2013.08.066. Epub 2013 Sep 6.

8.

The challenge of developing a herpes simplex virus 2 vaccine.

Dropulic LK, Cohen JI.

Expert Rev Vaccines. 2012 Dec;11(12):1429-40. doi: 10.1586/erv.12.129. Review.

9.

Epidemiological impact of a genital herpes type 2 vaccine for young females.

Lou Y, Qesmi R, Wang Q, Steben M, Wu J, Heffernan JM.

PLoS One. 2012;7(10):e46027. doi: 10.1371/journal.pone.0046027. Epub 2012 Oct 11.

10.

Optimal but unequitable prophylactic distribution of vaccine.

Keeling MJ, Shattock A.

Epidemics. 2012 Jun;4(2):78-85. doi: 10.1016/j.epidem.2012.03.001. Epub 2012 Mar 7. Review.

11.

The ongoing pursuit of a prophylactic HSV vaccine.

Chung E, Sen J.

Rev Med Virol. 2012 Sep;22(5):285-300. doi: 10.1002/rmv.1709. Epub 2012 Mar 7. Review.

PMID:
22396215
12.

HSV-2: in pursuit of a vaccine.

Johnston C, Koelle DM, Wald A.

J Clin Invest. 2011 Dec;121(12):4600-9. doi: 10.1172/JCI57148. Epub 2011 Dec 1. Review.

13.

Immunology. Painful failure of promising genital herpes vaccine.

Cohen J.

Science. 2010 Oct 15;330(6002):304. doi: 10.1126/science.330.6002.304. No abstract available.

PMID:
20947733
14.

AUTOGENOUS RESIDUAL VACCINES: THE THERAPEUTIC RESULTS OBTAINED IN A SERIES OF 360 CASES.

Jenkins CE.

Br Med J. 1928 Mar 3;1(3504):340-2. No abstract available.

15.

On Accidentally Spurious or Impure, and Effete or Imperfect, Vaccination.

Startin J.

Br Med J. 1871 Jun 3;1(544):584-5. No abstract available.

16.
17.

Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.

Alsallaq RA, Schiffer JT, Longini IM Jr, Wald A, Corey L, Abu-Raddad LJ.

Sex Transm Dis. 2010 May;37(5):290-7. doi: 10.1097/OLQ.0b013e3181d3d023.

18.

The Therapeutic Employment of Vaccines.

Meakins JC.

Can Med Assoc J. 1915 Jul;5(7):593-602. No abstract available.

19.

An sveir model for assessing potential impact of an imperfect anti-sars vaccine.

Gumel AB, McCluskey CC, Watmough J.

Math Biosci Eng. 2006 Jul;3(3):485-512.

PMID:
20210376
20.

[Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].

Barkhaleva OA, Ladyzhenskaia IP, Vorob'eva MS, Shalunova NV, Podcherniaeva RIa, Mikhaĭlova GR, Khorosheva TV, Barinskiĭ IF.

Vopr Virusol. 2009 Sep-Oct;54(5):33-7. Russian.

PMID:
19882901
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk